Investing

Catalyst Pharmaceuticals : CPRX

CPRX

Stock Data

$22.70

$0.26 (1.13%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Catalyst Pharmaceuticals is a biopharmaceutical company based in Coral Gables, Florida, dedicated to developing treatments for rare neuromuscular and neurological diseases. Its flagship product, Firdapse, is designed to help patients with Lambert-Eaton Myasthenic Syndrome (LEMS), including a pediatric version named Ruzurgi. The company is also exploring Firdapse's potential for other conditions like MuSK antibody positive myasthenia gravis and spinal muscular atrophy. Catalyst Pharmaceuticals collaborates with industry partners to expand its product offerings, including a partnership for generic medication development.

All Catalyst Pharmaceuticals Articles

19 Articles

Lee Jackson | Aug 22, 2023 at 8:55 AM EDT

Tuesday’s Top Wall Street Upgrades and Downgrades: Applied Materials, CVS Health, Hawaiian Electric Industries, Walmart and More

Tuesday's top analyst upgrades and downgrades included Applied Materials, Bill, Catalyst Pharmaceutical, CVS Health, Elastic, Hawaiian Electric Industries and Walmart.

Chris Lange | Aug 24, 2022 at 11:05 AM EDT

Fed Anticipation: Analysts Upgrade or Downgrade Amazon, Macy’s, Twitter and More

Wednesday's additional top analyst upgrades and downgrades were on Amazon.com, Beyond Meat, Catalyst Pharmaceuticals, Dick’s Sporting Goods, Macy’s, Medtronic, Twitter,…

Douglas A. McIntyre | Jan 29, 2021 at 7:37 AM EST

Catalyst Pharma, TherapeuticsMD May Be Next WallStreetBets Targets

The "next" GameStop is certain to be hit fast and hard. Perhaps the WallStreetBets message board on Reddit will target…

Jon C. Ogg | Sep 24, 2020 at 11:32 AM EDT

Catalyst Pharmaceuticals Looks Cheap, but Few Catalysts for Massive Upside

Some small-cap companies will screen as having deep value, but many value stocks are deemed to be "cheap" because they…

Douglas A. McIntyre | Sep 5, 2020 at 6:31 AM EDT

These Are The Robinhood Stocks With The Highest Analyst Rating

Robinhood has become the dominant discount brokerage platform over the last year. It had 4.3 million average revenue trades in…

Douglas A. McIntyre | Aug 31, 2020 at 6:39 AM EDT

These Popular Robinhood Stocks Could Wreck Its Traders

Some companies Robinhood traders find most attractive are very risky bets. A hit to the financials of one of these…

Lee Jackson | Mar 21, 2017 at 10:25 AM EDT

5 Biotech Stocks That Could Skyrocket From Upcoming Catalysts

A new SunTrust Robinson Humphrey research report focuses in on biotech companies that have upcoming clinical data that could prove…

Chris Lange | Mar 15, 2017 at 12:10 PM EDT

Wednesday’s Biggest Biopharma Movers

The broad markets are inching forward on Wednesday after hitting new highs in what has been known as the Trump…

Jon C. Ogg | Oct 5, 2016 at 8:40 AM EDT

Top Analyst Upgrades and Downgrades: Broadcom, Flex, Genworth, Micron, Salesforce, UBS, Wal-Mart and More

The the top analyst upgrades, downgrades and initiations seen on Wednesday morning include Broadcom, Flex, Genworth Financial, Micron Technology, Salesforce.com,…

Chris Lange | May 1, 2016 at 10:55 AM EDT

5 Companies That Destroyed Shareholders Last Week

Apple, Twitter and other companies punished shareholders last week, and analysts expect more earnings disappointments going forward.

Chris Lange | Apr 26, 2016 at 11:05 AM EDT

Why This Isn’t the End of Catalyst Pharmaceuticals

Catalyst Pharmaceuticals saw its shares get halved just Tuesday morning alone, following a business update regarding its Lambert-Eaton myasthenic syndrome…

Chris Lange | Feb 11, 2015 at 11:25 AM EST

Rite Aid PBM Purchase Differentiates It From CVS and Walgreens

Rite Aid has announced that it will acquire EnvisionRx for $2 billion from the private equity firm TPG Capital.

Chris Lange | Sep 30, 2014 at 4:18 PM EDT

What Else Is Under the Hood for Catalyst Pharma?

ThinkstockCatalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) announced positive topline results from its Phase 3 clinical trial of Firdapse for the…

Paul Ausick | Aug 27, 2013 at 4:14 PM EDT

Tuesday Closing Bell: Markets Sink on Syria Worries

August 27, 2013: U.S. markets opened lower Tuesday morning with worries over possible U.S. actions in Syria weighing prices down…

Paul Ausick | Apr 23, 2013 at 4:29 PM EDT

Market Close: Big Winners & Losers for April 23, 2013

thinkstockHere are today’s five biggest gaining stocks at closing: Superconductor Technologies Inc. (NASDAQ: SCON) is up 134.9% at $5.45. MEMSIC…